• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Pembrolizumab with radiotherapy and surgery improves survival in high-risk soft tissue sarcoma

byNeel MistryandTeddy Guo
December 19, 2024
in Chronic Disease, Oncology, Orthopedic Surgery, Surgery
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Pembrolizumab plus radiotherapy and surgery significantly improved disease-free survival.

2. Grade 3 or higher adverse events were more common in the pembrolizumab group compared to control.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Many patients with localized, high-risk soft tissue sarcomas develop metastatic disease. Immunotherapy, such as pembrolizumab, has shown potential when combined with conventional therapies such as radiotherapy and surgery. This randomized controlled trial aimed to evaluate whether adding pembrolizumab to preoperative radiotherapy and surgery could improve disease-free survival in patients with stage III undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma of the extremity. The primary outcome of this study was disease-free survival, while a key secondary outcome was the assessment of safety and adverse event rates between treatment groups. According to study results, pembrolizumab significantly increased disease-free survival compared to the control group but was associated with a higher rate of severe adverse events. Although this study was well done, it was limited by a modest sample size, affecting the generalizability of results.

Click to read the study in The Lancet

Relevant Reading: Doxorubicin–Trabectedin with Trabectedin Maintenance in Leiomyosarcoma

RELATED REPORTS

2 Minute Medicine Rewind June 30, 2025

Evaluating scar outcomes in pediatric burn patients following skin grafting 

Transcatheter closure of patent ductus arteriosus demonstrates similar outcomes compared to surgical repair

In-depth [randomized controlled trial]: Between Nov 18, 2017, and Nov 14, 2023, 143 patients were screened for eligibility across 20 institutions in Australia, Canada, Italy, and the USA. Patients with grade 2 or 3, stage III undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma of the extremities were included. Altogether, 127 patients were included in the final analysis. The addition of pembrolizumab to preoperative radiotherapy and surgery significantly improved disease-free survival (hazard ratio [HR] 0.61, 90% confidence interval [CI] 0.39-0.96), increasing the 2-year survival rate by 15% compared to the control group. The secondary outcome revealed a higher incidence of grade 3 or greater adverse events (56% in pembrolizumab vs. 31% in control). Findings from this study suggest that pembrolizumab combined with preoperative radiotherapy and surgery is a promising approach to improve disease-free survival in high-risk soft tissue sarcoma.

Image: PD

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: adjuvant radiotherapyimmunotherapyorthopedic surgeryPembrolizumabradiotherapysarcomaSurgery
Previous Post

#VisualAbstract: Cadonilimab Plus Chemotherapy Improves Survival in Recurrent or Metastatic Cervical Cancer

Next Post

#VisualAbstract: Blinatumomab Improves Survival in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children

RelatedReports

Quick Take: Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial
Weekly Rewinds

2 Minute Medicine Rewind June 30, 2025

June 30, 2025
Pediatrics

Evaluating scar outcomes in pediatric burn patients following skin grafting 

June 26, 2025
Colchicine may lower the risk of cardiovascular events in patients with coronary disease
Cardiology

Transcatheter closure of patent ductus arteriosus demonstrates similar outcomes compared to surgical repair

June 13, 2025
Prognostic indicators for transarterial chemoembolization in patients with hepatocellular carcinoma with extrahepatic spread identified
AI Roundup

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer

June 12, 2025
Next Post
#VisualAbstract: Blinatumomab Improves Survival in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children

#VisualAbstract: Blinatumomab Improves Survival in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children

Poor glycemic control not associated with greater number of antibiotic prescription in diabetic patients

European data showed coffee consumption associated with lower mortality

Coffee consumption associated with better cognitive performance in patients with atrial fibrillation

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2 Minute Medicine Rewind June 30, 2025
  • Weighted vests and resistance training confer similar outcomes for bone density in the elderly
  • Breast cancer survivors may have a lower risk of Alzheimer’s dementia
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.